OncoSec Medical Inc (OTCMKTS:ONCS), ImmunoPulse Trails ‘Positive’


Dallas, Texas 01/10/2014 (FINANCIALSTRENDS) – OncoSec Medical Inc (OTCMKTS:ONCS) is an innovative oncology domain product and therapy maker, designer and developer, operating from San Diego. The $92.25 million market cap company trades in volumes of 6.27 million and trades at $0.540 per share.

Solid tumor therapies for non-efficacy segment

The company, has been bridging the gap in the areas of cancers, which lacks treatment due to non-efficacy status of some of the approved therapies or are yet to be developed for cancers of the solid tumour type. Incidentally, the company operates the therapeutic approach under its OncoSec Medical Systems and involves the use of electroporation device for delivery, which is used in combination with an approved drug. The drugs are usually in chemotherapeutic drug along with a cytokine for dealing with solid tumors.

Two Melanoma drugs

OncoSec Medical Inc (OTCMKTS:ONCS) also has two of its most popular drugs — Tafinlar and Mekinist for the treatment of melanoma in the metastatic stage. Both of these drugs are delivered as oral treatment and are single-agent-based ensuring a second-line of treatment for those types of metastatic melanoma which is un-resectable.

OncoSec Medical Inc (OTCMKTS:ONCS) in the second week of December posted that, the ‘interim data’ for the Phase II study of OMS-1 100, was positive indicating, ImmunoPulse is safe for use. The clinical trials also recorded other results- positive response, while two of the patients revealed a beneficial stabilization in the disease.

OncoSec Medical Inc (OTCMKTS:ONCS) in its earlier results had showed that ImmunoPulse which is its  immunotherapy product was effective in lowering turmors in mice. The mice which were treated singly with ImmunoPulse as well as in combination with others showed regression and no-deaths were reported either. Following the success of ImmunoPulse the company had pursued other melanoma manifestations, so as to conduct human trials eventually for ImmunoPluse. The metastatic Melanoma results appear to take the drug in the right direction.